A retrospective study assessing the efficacy and safety of ustekinumab in patients with moderate to severe crohn's disease in brazil
Latest Information Update: 04 Jul 2021
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 04 Jul 2021 New trial record
- 23 May 2021 Results presented at the Digestive Disease Week 2021